拓扑异构酶Ⅰ和Ⅱ双重抑制剂的研究进展

蒋琰; 盛春泉; 董国强

doi:10.3969/j.issn.1006-0111.2015.04.004

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

x 关闭永久关闭

应中央军委要求，2022年9月起，《药学实践杂志》将更名为《药学实践与服务》，双月刊，正文96页；2023年1月起，拟出版月刊，正文64页，数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿！

拓扑异构酶Ⅰ和Ⅱ双重抑制剂的研究进展

蒋琰, 盛春泉, 董国强

文章导航 > 药学实践与服务 > 2015 > 33(4): 303-308,379

蒋琰, 盛春泉, 董国强. 拓扑异构酶Ⅰ和Ⅱ双重抑制剂的研究进展[J]. 药学实践与服务, 2015, 33(4): 303-308,379. doi: 10.3969/j.issn.1006-0111.2015.04.004

引用本文:

蒋琰, 盛春泉, 董国强. 拓扑异构酶Ⅰ和Ⅱ双重抑制剂的研究进展[J]. 药学实践与服务, 2015, 33(4): 303-308,379. doi: 10.3969/j.issn.1006-0111.2015.04.004

JIANG Yan, SHENG Chunquan, DONG Guoqiang. Research progress of dual topoisomerase Ⅰ and Ⅱ inhibitors[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(4): 303-308,379. doi: 10.3969/j.issn.1006-0111.2015.04.004

Citation:

JIANG Yan, SHENG Chunquan, DONG Guoqiang. Research progress of dual topoisomerase Ⅰ and Ⅱ inhibitors[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(4): 303-308,379. doi: 10.3969/j.issn.1006-0111.2015.04.004

拓扑异构酶Ⅰ和Ⅱ双重抑制剂的研究进展

doi: 10.3969/j.issn.1006-0111.2015.04.004

第二军医大学药学院药物化学教研室, 上海 200433

Research progress of dual topoisomerase Ⅰ and Ⅱ inhibitors

Department of Medicinal Chemistry, School of Pharmacy, Second Military Medical University, Shanghai 200433, China

摘要: 拓扑异构酶(topoisomerases,Tops)是参与调节细胞内DNA复制、转录、重组和修复等过程的必需酶。Tops分为TopⅠ和TopⅡ,两者通过DNA切断和连接,维持DNA正常拓扑结构和代谢过程。由于Tops在DNA代谢过程的重要作用,干扰Tops的催化活性或者诱导产生Tops介导的DNA损伤已经成为抗肿瘤治疗的重要策略。Tops已经成为最重要的抗肿瘤靶点之一。综述近年来Tops双重抑制剂的研究进展。
- TopⅠ /
- TopⅡ /
- 双重抑制剂 /
- 抗肿瘤药物
Abstract: DNA topoisomerases (Tops) are essential enzymes that regulate the cellular processes such as replication, transcription, recombination and repair. DNA Tops can be classified into two types, topoisomerase Ⅰ (TopⅠ) and topoisomerase Ⅱ (TopⅡ). They catalyze the breakage and religation of DNA, maintaining the topological changes of DNA and various DNA metabolic processes. Due to their important role in DNA metabolism, the ability to interfere with the functions of Tops or generating Top-mediated DNA damage is an effective strategy for cancer chemotherapy. Tops have been considered as the most important targets for tumor chemotherapy. In this review, we used examples to describe the development of dual topoisomerase Ⅰ and Ⅱ inhibitors.
- topoisomerase Ⅰ /
- topoisomerase Ⅱ /
- dual inhibitors /
- anticancer drugs

[1]	Wall ME, Wani MC, Cook CE, et al. Plant antitumor agents Ⅰ. The isolation and structure of camptothecin, a noveⅠ alkaloidal leukemia and tumor inhibitor from camptotheca acuminata1,2[J]. J Am Chem Soc, 1966, 88(16): 3888-3890.
[2]	Hsiang YH, Hertzberg R, Hecht S, et al. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase Ⅰ[J]. J Biol Chem, 1985, 260(27): 14873-14878.
[3]	Dallavalle S, Gattinoni S, Mazzini S, et al. Synthesis and cytotoxic activity of a new series of topoisomerase Ⅰ inhibitors[J]. Bioorg Med Chem Lett, 2008, 18(4): 1484-1489.
[4]	Kruczynski A, Barret JM, Van Hille B, et al. Decreased nucleotide excision repair activity and alterations of topoisomerase Ⅱ alpha are associated with the in vivo resistance of a P388 leukemia subline to F11782, a novel catalytic inhibitor of topoisomerases Ⅰ and Ⅱ[J]. Clin Cancer Res, 2004, 10(9): 3156(3168.
[5]	Kluza J, Mazinghien R, Irwin H, et al. Relationships between DNA strand breakage and apoptotic progression upon treatment of HL(60 leukemia cells with tafluposide or etoposide[J]. Anticancer Drugs, 2006, 17(2): 155(164.
[6]	Mucci(LoRusso P, Polin L, Bissery MC, et al. Activity of batracylin (NSC-320846) against solid tumors of mice[J]. Invest New Drugs, 1989, 7(4): 295-306.
[7]	Plowman J, Paull KD, Atassi G, et al. Preclinical antitumor activity of batracylin (NSC 320846)[J]. Invest New Drugs, 1988, 6(3): 147-153.
[8]	Rao VA, Agama K, Holbeck S, et al. Batracylin (NSC 320846), a dual inhibitor of DNA topoisomerases Ⅰ and Ⅱ induces histone gamma-H2AX as a biomarker of DNA damage[J]. Cancer Res, 2007, 67(20): 9971-9979.
[9]	Lewis LJ, Mistry P,Charlton PA,et al. Mode of action of the novel phenazine anticancer agents XR11576 and XR5944. Anticancer Drugs 2007, 18, 139-48.
[10]	de Jonge MJ, Kaye S, Verweij J, et al. Phase I and pharmacokinetic study of XR11576, an oral topoisomerase Ⅰ and Ⅱ inhibitor, administered on days 1-5 of a 3-weekly cycle in patients with advanced solid tumours[J]. Br J Cancer, 2004, 91(8): 1459-1465.
[11]	Verborg W, Thomas H, Bissett D, et al. First-into-man phase Ⅰ and pharmacokinetic study of XR5944.14, a novel agent with a unique mechanism of action[J]. Br J Cancer, 2007, 97(7): 844-850.
[12]	Montaner B, Castillo-Avila W, Martinell M, et al. DNA interaction and dual topoisomerase Ⅰ and Ⅱ inhibition properties of the anti-tumor drug prodigiosin[J]. Toxicol Sci, 2005, 85(2): 870-879.
[13]	Montaner B, Navarro S, Pique M, et al. Prodigiosin from the supernatant of Serratia marcescens induces apoptosis in haematopoietic cancer cell lines[J]. Br J Pharmacol, 2000, 131(3): 585-593.
[14]	Montaner B, Perez-Tomas R. Prodigiosin-induced apoptosis in human colon cancer cells[J]. Life Sci, 2001, 68(17): 2025-2036.
[15]	Lin JK. Molecular targets of curcumin[J]. Adv Exp Med Biol, 2007, 595: 227-243.
[16]	Lopez-Lazaro M, Willmore E, Jobson A, et al. Curcumin induces high levels of topoisomerase Ⅰ-and Ⅱ-DNA complexes in K562 leukemia cells[J]. J Nat Prod, 2007, 70(12): 1884-1888.
[17]	Dhandapani KM, Mahesh VB,Brann DW. Curcumin suppresses growth and chemoresistance of human glioblastoma cells via AP-Ⅰ and NF kappaB transcription factors[J]. J Neurochem, 2007, 102(2): 522-538.
[18]	Chih LL,Jen KL. Curcumin: a potential cancer chemopreventive agent through suppressing NF-κB signaling[J]. J Cancer Mol, 2008, 4(1): 11-16.
[19]	Choi JY, Seo CS, Zheng MS, et al. Topoisomerase Ⅰ and Ⅱ inhibitory constituents from the bark of Tilia amurensis[J]. Arch Pharm Res, 2008, 31(11): 1413-1418.
[20]	Ishiyama D, Kanai Y, Senda H, et al. Novel human topoisomerase Ⅰ inhibitors, topopyrones A, B, C and D. Ⅱ. Structure elucidation[J]. J Antibiot (Tokyo), 2000, 53(9): 873-878.
[21]	Kanai Y,Ishiyama D,Senda H,et al. Novel human topoisomerase Ⅰ inhibitors, topopyrones A, B, C and D. Ⅰ. Producing strain, fermentation, isolation, physico-chemical properties and biological activity. J Antibiot (Tokyo) 2000, 53, 863-72.
[22]	Khan QA, Elban MA; Hecht SM. The topopyrones poison human DNA topoisomerases Ⅰ and Ⅱ[J]. J Am Chem Soc, 2008, 130(39): 12888-12889.
[23]	Hecht SM, Khan QA, Maini R, et al. Topopyrones: Dual topoisomerase inhibitors. Patent PCT/US2009/050081, 2010.
[24]	López-Lázaro M, Willmore E,Austin CA. The dietary flavonoids myricetin and fisetin act as dual inhibitors of DNA topoisomerases Ⅰ and Ⅱ in cells[J]. Mutat Res, 2010, 696:41-47.
[25]	Demarquay D, Huchet M, Coulomb H, et al. BN80927: A novel homocamptothecin that inhibits proliferation of human tumor cells in vitro and in vivo[J]. Cancer Res, 2004, 64:4942-4949.
[26]	Lavergne O, Demarquay D, Bailly C, et al. Topoisomerase Ⅰ-mediated antiproliferative activity of enantiomerically pure fluorinated homocamptothecins[J]. J Med Chem, 2000, 43(11): 2285-2289.
[27]	Taniguchi K, Kohno K, Kawanami K, et al. Drug-induced down-regulation of topoisomerase Ⅰ in human epidermoid cancer cells resistant to saintopin and camptothecins[J]. Cancer Res, 1996, 56(10): 2348-2354.
[28]	Basnet A, Thapa P, Karki R, et al. 2,4,6-Trisubstituted pyridines: synthesis, topoisomerase Ⅰ and Ⅱ inhibitory activity, cytotoxicity, and structure-activity relationship[J]. Bioorg Med Chem, 2007, 15(13): 4351-4359.
[29]	Dalla Via L, Magno SM, Gia O, et al. Benzothiopyranoindole-based antiproliferative agents: synthesis, cytotoxicity, nucleic acids interaction, and topoisomerases inhibition properties[J]. J Med Chem, 2009, 52(17): 5429-5441.

[1]	宋雨桐, 夏德润, 顾珩, 唐少文, 易洪刚, 沃红梅. 帕博利珠单抗与铂类化疗方案在晚期非小细胞肺癌一线治疗中的药物经济学评价 . 药学实践与服务, 2024, 42(8): 334-340. doi: 10.12206/j.issn.2097-2024.202303023
[2]	张艺昕, 关欣怡, 王博宁, 闻俊, 洪战英. 二氢吡啶类钙离子拮抗药物手性分析及其立体选择性药动学研究进展 . 药学实践与服务, 2024, 42(8): 319-324. doi: 10.12206/j.issn.2097-2024.202308062
[3]	夏哲炜, 曾垣烨, 朱海菲, 李育, 陈啸飞. 核磁共振磷谱法测定磷酸氢钙咀嚼片中药物含量 . 药学实践与服务, 2024, 42(9): 399-401, 406. doi: 10.12206/j.issn.2097-2024.202404063
[4]	孙丹倪, 黄勇, 张嘉宝, 王培. 代谢相关脂肪性肝病的无创诊断与药物治疗 . 药学实践与服务, 2024, 42(10): 411-418. doi: 10.12206/j.issn.2097-2024.202403049
[5]	陈怡君, 王卓, 何苗, 张宇, 田泾. 泌尿系统碎石术抗菌药物预防使用合理管控实践 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202402034
[6]	杨媛媛, 安晓强, 许佳捷, 江键, 梁媛媛. 正极性驻极体联合5-氟尿嘧啶对瘢痕成纤维细胞生长抑制的协同作用 . 药学实践与服务, 2024, 42(6): 244-247. doi: 10.12206/j.issn.2097-2024.202310027
[7]	张岩, 李炎君, 刘家荟, 邓娇, 原苑, 张敬一. 药物性肝损伤不良反应分析 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202404034
[8]	张元林, 宋凯, 孙蕊, 舒飞, 舒丽芯, 杨樟卫. 基于真实世界数据的药物利用研究综述 . 药学实践与服务, 2024, 42(6): 238-243. doi: 10.12206/j.issn.2097-2024.202312010
[9]	刘汝雄, 杨万镇, 涂杰, 盛春泉. 铁死亡调控蛋白GPX4的小分子抑制剂研究进展 . 药学实践与服务, 2024, 42(9): 375-378. doi: 10.12206/j.issn.2097-2024.202312075

点击查看大图

计量

文章访问数: 4860
HTML全文浏览量: 826
PDF下载量: 929
被引次数: 0

拓扑异构酶Ⅰ和Ⅱ双重抑制剂的研究进展

doi: 10.3969/j.issn.1006-0111.2015.04.004

第二军医大学药学院药物化学教研室, 上海 200433

收稿日期: 2013-10-15
修回日期: 2014-02-19

关键词:

TopⅠ /

TopⅡ /

双重抑制剂 /

抗肿瘤药物

摘要: 拓扑异构酶(topoisomerases,Tops)是参与调节细胞内DNA复制、转录、重组和修复等过程的必需酶。Tops分为TopⅠ和TopⅡ,两者通过DNA切断和连接,维持DNA正常拓扑结构和代谢过程。由于Tops在DNA代谢过程的重要作用,干扰Tops的催化活性或者诱导产生Tops介导的DNA损伤已经成为抗肿瘤治疗的重要策略。Tops已经成为最重要的抗肿瘤靶点之一。综述近年来Tops双重抑制剂的研究进展。